Triple therapy in the treatment of patients with a combination of chronic obstructive pulmonary disease and bronchial asthma
- Authors: Trushina E.Y.1, Kostina E.M.1, Tipikin V.A.1, Orlova E.A.1
-
Affiliations:
- Penza Institute for Advanced Medical Training – Campus Branch of the RMACPE
- Issue: Vol 31, No 1 (2024)
- Pages: 108-112
- Section: Pulmonology/ENT/ARVI
- URL: https://journal-vniispk.ru/2073-4034/article/view/275676
- DOI: https://doi.org/10.18565/pharmateca.2024.1.108-112
- ID: 275676
Cite item
Open Access
Access granted
Subscription Access
Abstract
Patients with a combination of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) are a special cohort that requires combination bronchodilator therapy in combination with glucocorticosteroid drugs. Patients with this pathology have difficulty achieving control of asthma and stabilization of COPD; they experience decreased lung function and frequent exacerbations requiring hospitalization, which leads to a decrease in quality of life. The possibilities for treating chronic obstructive diseases of the respiratory system have expanded significantly in recent years, primarily due to the emergence of new combination drugs. The International Guide for Global Initiative for Chronic Obstructive Lung Disease (2023) recommends starting treatment with triple inhalation therapy, including long-acting β2-agonists, long-acting anticholinergics, and inhaled glucocorticosteroids. This article presents data from studies of the clinical efficacy and safety of a fixed triple combination of beclomethasone dipropionate, glycopyrronium bromide and formoterol fumarate, available in the form of an extra-fine aerosol, which made it possible to optimize inhalation therapy in patients with a combination of BA and COPD.
Full Text
##article.viewOnOriginalSite##About the authors
Elena Yu. Trushina
Penza Institute for Advanced Medical Training – Campus Branch of the RMACPE
Author for correspondence.
Email: trushina.lena@mail.ru
ORCID iD: 0000-0001-5673-9195
SPIN-code: 2164-6580
Cand. Sci. (Med.), Associate Professor at the Department of Pulmonology and Phthisiology
Russian Federation, PenzaE. M. Kostina
Penza Institute for Advanced Medical Training – Campus Branch of the RMACPE
Email: trushina.lena@mail.ru
ORCID iD: 0000-0003-1797-8040
SPIN-code: 2111-8827
Russian Federation, Penza
V. A. Tipikin
Penza Institute for Advanced Medical Training – Campus Branch of the RMACPE
Email: trushina.lena@mail.ru
ORCID iD: 0009-0000-0990-4661
SPIN-code: 7403-8592
Russian Federation, Penza
E. A. Orlova
Penza Institute for Advanced Medical Training – Campus Branch of the RMACPE
Email: trushina.lena@mail.ru
ORCID iD: 0000-0002-3902-2018
SPIN-code: 1700-4848
Russian Federation, Penza
References
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2023. Accessed January 16, 2023. URL: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD (2024). Accessed January 16, 2024. URL: https://goldcopd.org/wp-content/uploads/2024/02/GOLD-2024_v1.2-11Jan24_WMV.pdf
- Uchida A., Sakaue K., Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol Intern. 2018;67:165–71. doi: 10.1016/j.alit.2018.02.002.
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59. doi: 10.1016/S0140-6736(17)32154-2.
- Трушина Е.Ю., Костина Е.М., Типикин В.А., Орлова Е.А. Современные представления о сочетании бронхиальной астмы и хронической обструктивной болезни легких. Фарматека. 2023; 30(14):106–111. [Trushina E.Yu., Kostina E.M., Tipikin V.A., Orlova E.A. Modern concepts on the combination of bronchial asthma and chronic obstructive pulmonary disease. Farmateka. 2023; 30(14):106–111. (In Russ.)]. doi: 10.18565/pharmateca.2023.14.106-111.
- Avdeev S.N., Nevzorova V.A., Kudelya L.M., et al. Issues of triple therapy of chronic obstructive pulmonary disease. Comments to the algorithm. A resolution of expert panel, June 13, 2018, Vladivostok. Pul’monol. 2019;29(3):365–74. doi: 10.18093/0869-0189-2019-29-3-365-374.
- Virchow J.C., Kuna P., Paggiaro P., et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394:1737–49. doi: 10.1016/S0140-6736 (19)32215-9.
- Singh D., Papi A., Corradi M., et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–73.
- Singh D., Corradi M., Spinola M., et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J COPD. 2017;12:2917–28. doi: 10.2147/COPD.S146822.
- Papi A., Vestbo J., Fabbri L., et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomized controlled trial. Lancet. 2018;391(10125):1076–84. doi: 10.1016/S0140-6736(18)30206-X.
- Usmani O.S. Treating the small airways. Respiration. 2012;84(6):441–53. doi: 10.1159/000343629.
- De Backer W., Devolder A., Poli G., et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23(3):137–48. doi: 10.1089/jamp.2009.0772.
- Singh D., Fabbri L.M., Corradi M., et al. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. Eur Respir J. 2019;53(5):1900235. doi: 10.1183/13993003.00235-2019.
- Singh D., Virchow J.C., Canonica G.W., et al. Extrafine triple therapy in patients with asthma and persistent airflow limitation. Eur Respir J. 2020;56(3):2000476. doi: 10.1183/13993003.00476-2020.
Supplementary files
